Customize your JAMA Network experience by selecting one or more topics from the list below.
Peripheral artery disease (PAD) commonly refers to lower extremity atherosclerosis and is estimated to affect more than 200 million people worldwide.1 Patients with PAD are at increased risk for major adverse cardiac events (MACE) (myocardial infarction [MI], ischemic stroke, and cardiovascular death) and major adverse limb events (MALE) (major amputation and acute limb ischemia). Among patients with symptomatic PAD, annual rates of MACE are 4% to 5%, and rates of MALE are 1% to 2%.2 These ischemic events are associated with increased platelet and thrombotic activity and are potentially mitigated by antiplatelet therapy, anticoagulant therapy, or both. Based on available evidence, antithrombotic therapies should be individualized based on clinical presentation.
Hess CN, Hiatt WR. Antithrombotic Therapy for Peripheral Artery Disease in 2018. JAMA. 2018;319(22):2329–2330. doi:https://doi.org/10.1001/jama.2018.5422
Create a personal account or sign in to: